Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Free Cash Flow (2022 - 2025)

Historic Free Cash Flow for TriSalus Life Sciences (TLSI) over the last 4 years, with Q3 2025 value amounting to -$3.9 million.

  • TriSalus Life Sciences' Free Cash Flow rose 6437.0% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year increase of 5072.92%. This contributed to the annual value of -$41.2 million for FY2024, which is 1950.12% up from last year.
  • According to the latest figures from Q3 2025, TriSalus Life Sciences' Free Cash Flow is -$3.9 million, which was up 6437.0% from -$7.2 million recorded in Q2 2025.
  • TriSalus Life Sciences' Free Cash Flow's 5-year high stood at -$425954.0 during Q1 2022, with a 5-year trough of -$22.9 million in Q3 2022.
  • Moreover, its 4-year median value for Free Cash Flow was -$9.3 million (2023), whereas its average is -$9.4 million.
  • As far as peak fluctuations go, TriSalus Life Sciences' Free Cash Flow plummeted by 236740.26% in 2023, and later soared by 6437.0% in 2025.
  • Over the past 4 years, TriSalus Life Sciences' Free Cash Flow (Quarter) stood at -$8.5 million in 2022, then fell by 12.16% to -$9.5 million in 2023, then soared by 39.71% to -$5.8 million in 2024, then surged by 31.82% to -$3.9 million in 2025.
  • Its Free Cash Flow was -$3.9 million in Q3 2025, compared to -$7.2 million in Q2 2025 and -$5.3 million in Q1 2025.